From Age Expansion to Operational Maturity in National LDCT Programs
In February 2026, South Korea announced a proposal to lower the starting age for national lung cancer screening from 54 to 50 as part of its Fifth National Cancer Control Plan (2026–2030).
This policy shift reflects a broader global trend. Across the United States, Europe, and parts of Asia-Pacific, countries are reconsidering eligibility criteria for low-dose CT (LDCT) screening in order to improve early detection rates and reduce lung cancer mortality.
However, expanding eligibility raises a critical operational question:
How do national screening systems maintain quality and consistency as volume increases?
The answer increasingly points toward one direction:
AI is no longer a “technology add-on.” It is becoming part of the screening infrastructure.
Screening Expansion Means Structural Complexity
LDCT screening is not a simple imaging workflow. Each scan generates hundreds of thin-slice images that must be carefully reviewed.
Large-scale studies such as the National Lung Screening Trial (NLST) demonstrated that
LDCT reduces lung cancer mortality. As a result, national screening programs have been implemented in multiple countries.
Yet when eligibility expands, the impact is not limited to a linear increase in scan numbers.
Screening expansion leads to:
- A surge in imaging volume
- Accumulation of longitudinal data
- Increased reader workload
- Growth in follow-up management complexity
Lung cancer screening is not a one-time diagnostic event. It is a longitudinal surveillance model.
Nodules must be tracked across time. Volume, density, and morphological changes must be compared precisely with prior studies. Small differences may alter management pathways.
As datasets accumulate, operational complexity increases exponentially—not linearly. This is where system maturity becomes decisive.
Standardization: The Core of National Screening Quality
At the national level, equity is fundamental.
Regardless of region, hospital, or individual reader, screening quality must remain consistent and reproducible.
This requires:
- Standardized reading protocols
- Quantitative measurement frameworks
- Structured reporting systems
- Longitudinal data management capabilities
National screening programs cannot rely solely on individual expertise. They require system-level reproducibility.
The Role of AI in Screening Environments
In this context, AI-based reading support functions not as an autonomous diagnostic tool, but as an operational layer that supports consistency and efficiency.
AI reading support systems may contribute by:
- Highlighting nodule candidates to reduce perceptual misses
- Providing automated 3D volumetry and Volume Doubling Time (VDT) calculations
- Supporting structured reporting
- Enabling quality assurance (QA) data accumulation
Importantly:
AI does not replace radiologists. Final interpretation and clinical decision-making remain the responsibility of qualified physicians.
The value of AI in screening programs lies not in automation, but in standardization and scalability.
From Algorithm Accuracy to Operational Stability
Historically, medical AI was evaluated primarily through performance metrics—sensitivity, specificity, AUC values.
In national screening programs, different criteria matter:
- Does the system function reliably across diverse CT scanners and protocols?
- Can it maintain consistency across multiple institutions?
- Does it integrate smoothly into existing PACS and reporting workflows?
- Can it support longitudinal follow-up management?
The question shifts from: “How accurate is the algorithm?”
to: “How well does the system operate at scale?”
This marks a transition from experimental validation to infrastructure integration.
National Cancer AI Platforms and Multimodal Integration
Several countries are now expanding centralized cancer data infrastructures to incorporate AI-ready architectures.
In South Korea, the National Cancer Data Center is being expanded into a National Cancer AI & Data Center, integrating imaging, genomic, and pathology data into a multimodal ecosystem.
This reflects a global movement:
Screening is no longer just about image interpretation.
It is about connecting detection, risk stratification, follow-up, and research within a unified system.
AI becomes the connective tissue between these layers.
Real-World Implementation: The ZORALCS Example
A strong example of real-world implementation is the
ZORALCS project (Zuid-Oost Rand Antwerps Longkanker Screeningsproject) in Belgium.
Unlike tightly controlled single-center trials, ZORALCS evaluated the feasibility of running a lung cancer screening program in a real regional, multicenter environment.
Key elements included:
- ESTI-guideline-based standardized protocols
- AI deployed as a second reader
- Automated 3D volumetry
- Automated VDT calculation
- Multicenter consistency management
ZORALCS demonstrated not merely AI performance, but operational feasibility in a distributed screening environment.
In this study, Coreline Soft’s AI software was adopted as the second reader and referenced in the publication as a state-of-the-art solution.
The significance lies not in the brand, but in the validation of AI within a real screening infrastructure.
Scaling Screening Systems Requires Infrastructure Thinking
As more countries expand lung cancer screening eligibility, the challenge will not be imaging capacity alone.
The real challenge is sustaining quality while scale increases.
Screening systems must evolve from: Isolated imaging workflows
to Structured, longitudinal, data-integrated infrastructures
AI reading support plays a role within that system—not as a standalone innovation, but as an enabling layer.
The Core Question Moving Forward
The central issue is not whether AI should be adopted.
The central issue is:
How can national screening programs be designed to remain stable, standardized, and scalable as participation grows?
As eligibility expands and longitudinal datasets accumulate, operational maturity becomes the defining factor of success.
In this environment, AI transitions from an experimental capability to part of the structural backbone of modern screening systems.
List
